NVS tops Q4 EPS estimates as margins expand, but revenues miss the mark amid U.S. generics hitting Entresto and Promacta, ...
The pharma major said it faces the largest drug-patent expiry headwind in its history this year.
Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter ...
Novartis forecast its first annual drop in operating profit in a decade on Wednesday, even as it indicated that long term, the company could potentially offset the patent expiry of its ...
FRANKFURT, Feb 4 (Reuters) - Swiss drugmaker Novartis forecast a decline in 2026 operating profit in the low single-digit percentage range on Wednesday, held back by competition from cheaper ...
MSN Laboratories Pvt. Ltd. can’t reopen disputes resolved in earlier litigation over the scope, validity, and infringement of ...
The Third Circuit and Federal Circuit this week turned back Novartis’s requests for injunctions to block a version of its heart failure medication Entresto from generic maker MSN ...
By Ludwig Burger and Bhanvi Satija FRANKFURT, Feb 4 (Reuters) - Swiss drugmaker Novartis forecast a worse-than-expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results